欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国精品久久久久久 | 欧美激情中文字幕一区二区 | 国产精品永久免费自在线观 | 成年免费大片黄在线观看免费 | 国产灌醉迷晕在线精品 | 成人永久 | 国产91在线播放中文 | 国产精品一国产精品一k频道 | 91精品欧美激情在线播放 | 高清无码 | 国产呦精品一区二区三区 | 三级欧美日本国产 | 国产又大又黑又粗免费视频 | 国产成人一区二区三区免费视 | 色欧美片视频在线观看 | 中文字幕一区二区三区乱码 | 日韩免费毛片 | 国产欧美亚洲精品a | 成人欧美一区二区三区黑人免费 | 日韩欧美国产黄片在线 | 亚洲男人的天堂在 | 亚洲色国产欧美日韩 | 农村穷山沟女人乱弄视频 | 亚洲中文字幕无码髙清 | 亚洲人成中文 | 日韩av毛片不卡一区二区三区 | 日韩人妻在线糖心v | 国产乱国产乱老熟300部视频 | 伊人影院蕉久 | 国产视频第二页 | 免费在线观看少妇中文 | 国产日韩av无码免费看 | 精品久久久久久无码 | 亚洲一区二区三区不卡在线播放 | 亚洲欧美日韩天堂精品 | 亚洲av无码专区国产乱码电影 | 午夜毛片大福利导航 | 一区二区在线免费视频 | 日韩av无遮挡在线观看 | 亚洲日本一区二区三区在线播放 | 成人精品一区二区91毛片不卡 |